Published in Obesity and Diabetes Week, May 15th, 2006
In a recently published article, scientists in Venezuela conducted a study "to assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine. Forty patients taking olanzapine (10 mg daily) were randomly allocated to a metformin (n=20; 850 to 1700 mg daily) or placebo (n=20) group in a 14-week double-blind study. Waist circumference (WC), BWG, body mass index (BMI) fasting glucose, insulin, and lipids were evaluated at baseline and at weeks 7 and 14 of treatment."
"At week 14, BWG (kg) was similar in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.